Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC)
post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be
treated on a randomized, multi-Institutional open label study to determine if treatment with
intramuscular T given on a dose/schedule designed to result in rapid cycling from the polar
extremes of supraphysiologic to near castrate levels [i.e. Bipolar Androgen Therapy (BAT)]
will improve primary and secondary objectives vs. enzalutamide as standard therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins